Plasma microbial cell-free DNA testing for early diagnosis of pulmonary mucormycosis in a kidney transplant recipient
- 1Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Jacksonville, FL, 32224, United States.
Abstract
Pulmonary mucormycosis is one of the most lethal invasive fungal infections encountered in solid organ transplant recipients, with mortality rates ranging from 43% to 73%. Early diagnosis is critical, yet conventional microbiologic methods including bronchoalveolar lavage cultures have limited sensitivity, and standard fungal biomarkers such as beta-D-glucan and galactomannan have no role in the detection of Mucorales species. This diagnostic gap frequently results in delayed treatment initiation, which has been associated with substantially worse outcomes. We present a case of a 67-year-old kidney transplant recipient who developed rapidly progressive pulmonary mucormycosis caused by Rhizopus microsporus in the setting of recent high-dose corticosteroid therapy for allograft rejection. Plasma cell-free DNA testing facilitated earlier diagnosis before histopathologic results returned, which contributed to successful treatment and survival in this patient with angioinvasive pulmonary mucormycosis. This case highlights the utility of plasma cell-free DNA testing in pulmonary mucormycosis and the critical importance of a multidisciplinary, combined medical–surgical approach, including early empiric antifungal therapy, aggressive surgical debridement, and immunosuppression reduction, in order to achieve disease cure.
Related
- Pulmonary mucormycosis due to Rhizopus homothallicus in a kidney transplant recipient complicated by massive hemoptysis: A case report with review of literature.
- Agonal time in donation after circulatory death lung donors and associations with early recipient pulmonary allograft function and long-term post-transplant outcomes
- Wearable echocardiography enables real-time perioperative monitoring in a pediatric liver transplant recipient with hepatopulmonary syndrome and pulmonary arteriovenous malformations: a case report.
- Nudix hydrolase 15 deficiency and azathioprine toxicity in a liver transplant recipient: A case report
- Anti-N-Methyl-D-Aspartate Receptor Encephalitis Presenting as Acute Psychosis in a Renal Transplant Recipient Under Chronic Immunosuppression
BibTeX
@article{piepenbrink2026plasma,
title = {{Plasma microbial cell-free DNA testing for early diagnosis of pulmonary mucormycosis in a kidney transplant recipient}},
author = {Blake Piepenbrink and Vidit Yadav and Bala Munipalli and Varun Bansal and Justin Oring},
journal = {IDCases},
year = {2026},
month = oct,
doi = {10.1016/j.idcr.2026.e02795},
url = {https://doi.org/10.1016/j.idcr.2026.e02795},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Plasma microbial cell-free DNA testing for early diagnosis of pulmonary mucormycosis in a kidney transplant recipient
AU - Blake Piepenbrink
AU - Vidit Yadav
AU - Bala Munipalli
AU - Varun Bansal
AU - Justin Oring
PY - 2026
DA - 2026/10/15
JO - IDCases
DO - 10.1016/j.idcr.2026.e02795
UR - https://doi.org/10.1016/j.idcr.2026.e02795
AB - Pulmonary mucormycosis is one of the most lethal invasive fungal infections encountered in solid organ transplant recipients, with mortality rates ranging from 43% to 73%. Early diagnosis is critical, yet conventional microbiologic methods including bronchoalveolar lavage cultures have limited sensitivity, and standard fungal biomarkers such as beta-D-glucan and galactomannan have no role in the detection of Mucorales species. This diagnostic gap frequently results in delayed treatment initiation, which has been associated with substantially worse outcomes. We present a case of a 67-year-old kidney transplant recipient who developed rapidly progressive pulmonary mucormycosis caused by Rhizopus microsporus in the setting of recent high-dose corticosteroid therapy for allograft rejection. Plasma cell-free DNA testing facilitated earlier diagnosis before histopathologic results returned, which contributed to successful treatment and survival in this patient with angioinvasive pulmonary mucormycosis. This case highlights the utility of plasma cell-free DNA testing in pulmonary mucormycosis and the critical importance of a multidisciplinary, combined medical–surgical approach, including early empiric antifungal therapy, aggressive surgical debridement, and immunosuppression reduction, in order to achieve disease cure.
SN - 2214-2509
ER -